Workflow
Lexaria Bioscience(LEXX) - 2023 Q4 - Annual Report
LEXXLexaria Bioscience(LEXX)2023-11-21 06:16

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [] to [] Commission file number 000-52138 Lexaria Bioscience Corp. (Exact name of registrant as specified in its charter) State or other jurisdiction of incorporat ...